European shares end flat as investors await for inflation test
For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.
Maersk shares surge fuelled by soaring freight rates
OX2 jumps 40% after cash offer from EQT
Updated at 1609 GMT
By Ankika Biswas and Johann M Cherian
May 13 (Reuters) -Europe's STOXX 600 closed flat on Monday, as investors geared up for a slew of economic data from the euro zone and a key U.S. inflation print later in the week that could test the benchmark index's record-breaking run.
The pan-European STOXX 600 .STOXX was little changed, not far away from record high levels. Automobiles .SXAP led sectoral gains, recovering from a four-day losing streak, while defence stocks .SXPARO were the worst hit with a 1.2% loss.
The benchmark index hit a record high on Friday, logging its biggest weekly gain since late January, of 3%, underpinned by strong corporate earnings. The STOXX 600 regained its momentum midway into May, after geopolitical tensions and monetary policy uncertainties saw it wilt in April.
All eyes will be on the U.S. producer and consumer prices inflation readings, due on Tuesday and Wednesday, which will further set the tone for the Federal Reserve's anticipated rate cuts this year.
Back home, the euro zone's final inflation and flash first-quarter GDP in the latter half of the week will be scrutinized to gauge the interest rate path for the European Central Bank, which has indicated a June cut, flagged uncertainties around policy outlook beyond that and stressed its independence from the Fed.
"Even though many ECB speakers have stressed independence from the Fed, history tells us that divergences over the last 25 years were in hindsight seen as missteps," analysts at ING Research wrote.
"Inflation dynamics tend to be linked and thus dismissing signs of reflation across the pond is ill-advised."
On the day, healthcare stocks gained, with Novo Nordisk NOVOb.CO in the lead with a 3% rise. Denmark's Medicines Agency said the country faced a supply shortage for two doses of the firm's Wegovy weight-loss drug in the coming months due to rising demand.
AP Moeller-Maersk MAERSKb.CO jumped 7% to top the main index, boosted by a rise in freight rates amid higher trade volumes and the Red Sea crisis.
Spanish pharmaceutical company Almirall ALM.MC advanced 1.3% after a first-quarter results beat and reiteration of its full-year profitability targets.
German consumer electronics firm Ceconomy CECG.DE climbed 6.2% after announcing full-year earnings above estimates.
On the flip side, Holcim HOLN.S lost 4% as the Swiss cement maker's stock was trading ex-dividend, while EDP EDP.LS dropped 3% after brokerage Goldman Sachs downgraded the stock to "neutral" from "buy".
OX2 OX2SE.ST surged 40% after private equity firm EQT EQTAB.ST said it had made a recommended cash offer to buy the Swedish renewable energy group for 16.4 billion crowns ($1.51 billion).
Reporting by Ankika Biswas and Johann M Cherian in Bengaluru; Editing by Sherry Jacob-Phillips, Mrigank Dhaniwala and Alex Richardson
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
